BioIVT, provider of research models and services for drug and diagnostic development, is supplying peripheral blood mononuclear cells (PBMCs) for Promega’s antibody-dependent Cellular Cytotoxicity (ADCC) bioassay bioassay, which uses PBMCs to mimic in vivo conditions and measure the ADCC of antibodies during drug development and characterisation.
“This new platform combines BioIVT’s high quality, physiologically representative PBMCs with Promega’s reliable, quantitative readout technology to deliver more consistent results than traditional primary cell ADCC bioassays,” said BioIVT Chief Commercial Officer Alan Findlater.
According to BioIVT, the PBMC ADCC bioassay is the first kit to offer ADCC-qualified PBMCs alongside Promega technologies. It incorporates a add-mix-read format and sensitive luminescent readout, yielding a robust assay window. There are a variety of assay formats, providing ADCC-qualified PBMC effector cells and a choice of popular target cells expressing a HiBiT fusion protein. Upon target-cell killing, a bright luminescent signal is generated.
“BioIVT was uniquely positioned to support this assay development. Promega staff pre-screened and evaluated many of our recallable donors to identify those that were most reactive in their assay. Consequently, Promega was able to enhance its kit and ensure that its customers receive optimal responses for their immuno-oncology research. We look forward to continuing to partner with Promega to develop additional bioassays using human primary cells,” Mr. Findlater added.
Image credit: ThisIsengineeringRAEng